FindTrial
Sign In

Construction and evaluation of follow-up system for treatment to target of and primary hyperuricemia and gout

Construction and evaluation of follow-up system for treatment to target of hyperuricemia and primary gout

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052608
Enrollment
Unknown
Registered
2021-11-02
Start date
2021-11-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hyperuricemia and gout

Interventions

Experimental group:Adjust the dosage of uric acid lowering drugs according to the level of blood uric acid

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. According to the 2015 gout classification criteria, a clear diagnosis of gout patients; 3. No regular uric acid-lowering therapy within half a year; 4. Voluntarily participate in the clinical cohort study.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with secondary hyperuricemia (such as kidney disease, blood system disease, tumor chemotherapy); 3. Abnormal liver function (ALT/AST > 2 times the upper limit of normal); 4. White blood cells and platelets are lower than the lower limit of the standard reference value; 5. Patients with severe heart, lung, central nervous system diseases or malignant tumors; 6. The researcher does not consider it suitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
Joint ultrasound;blood uric acid;—

Countries

China

Contacts

Public ContactYe Lingying

Shanghai Changzheng Hospital

yelingying@smmu.edu.cn+86 13795393384

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026